Truqap 200 mg Film-Coated Tablets: Uses, Safety & Key Facts

What Truqap 200 mg film-coated tablets are used for

Truqap 200 mg film-coated tablets are described in the source content as a treatment for adults with HR-positive, HER2-negative advanced or metastatic breast cancer. It is used with fulvestrant in patients with certain genetic alterations.

The source content highlights the following markers: PIK3CA, AKT1, and PTEN. These markers are important because they help identify patients who may be considered for this treatment approach.

Truqap may also be considered in people whose cancer has not responded well to previous endocrine therapy, according to the original content.

How Truqap is taken

The original content states that the recommended schedule is 400 mg by mouth twice daily for four consecutive days, followed by a three-day break.

Because this is a prescription cancer medicine, the exact schedule, timing, and any dose adjustments should be confirmed with the treating team. Patients should follow the instructions on the prescription label and the official leaflet.

It is also important to take the tablets consistently as directed by the healthcare provider.

Who should not use Truqap

The source content says Truqap should not be used in people with a known hypersensitivity to any component of the medicine.

It also notes caution in people with a history of significant liver impairment or severe renal dysfunction, because the effects in these groups have not been adequately studied in the original material.

Pregnancy and breastfeeding are also highlighted as situations that require careful medical counselling.

Warnings and precautions

One of the main warnings mentioned in the source content is hyperglycemia. Regular blood glucose monitoring may be recommended by the treating team.

Diarrhea is another important issue mentioned in the original text. Staying hydrated and reporting severe or persistent symptoms promptly are sensible safety steps.

Any signs of an allergic reaction, such as rash or breathing difficulty, should be treated as urgent and reported immediately.

Possible adverse reactions

The source content lists hyperglycemia and diarrhea as common adverse reactions. It also mentions nausea, fatigue, and rash.

Serious reactions can occur with many cancer medicines, so new or worsening symptoms should always be discussed with a healthcare professional.

Drug interactions

Truqap may interact with other medicines, especially those metabolized by the liver. The source content specifically mentions CYP3A inhibitors, which may increase capivasertib levels in the bloodstream.

Patients should tell their doctor or pharmacist about all prescription medicines, over-the-counter products, and supplements they use. This helps the healthcare team check for possible interactions.

How Truqap works

The active ingredient in Truqap is capivasertib. The source content describes it as an AKT pathway inhibitor.

By targeting this pathway, capivasertib is intended to interfere with signals that support cancer cell growth and survival. The original content links this mechanism to treatment of selected patients with HR-positive, HER2-negative breast cancer.

Key points to verify with a doctor or pharmacist

• Whether the cancer type and biomarker results match the treatment criteria.
• The exact dosing schedule and what to do if a dose is missed.
• Which blood tests or glucose checks are needed during treatment.
• Whether any current medicines or supplements may interact.
• What symptoms should trigger urgent medical advice.

Frequently asked questions